Senti Biosciences, Inc. (SNTI) Institutional Ownership

Ownership Summary

Senti Biosciences, Inc. (NASDAQ:SNTI) is held by 15 institutional investors per 13F filings through December 2025.

• Collectively, these holders controlled 21.4% of Senti Biosciences's outstanding shares in December 2025, down from 22.3% in September 2025.
• They increased total shares held in Senti Biosciences by 2.37% from the prior quarter, while the number of investors in SNTI decreased 11.76% year over year.
• Of these 15 funds, 8 grew their exposure to Senti Biosciences, 2 cut back, and 5 maintained positions.
• Combined, these investors held 5.61Mn shares in SNTI for December 2025, up by 129.79K shares quarter on quarter, and up 4.69Mn shares year over year.
• NEA Management Company, LLC is the top holder of Senti Biosciences as of December 31, 2025, with 3.78Mn shares representing 14.4% of outstanding stock.
• The largest buyers of Senti Biosciences for the quarter ending December 2025 were Virtu Financial LLC (44.41K), JANE STREET GROUP, LLC (38.43K), MSOP GP, L.L.C. (35.74K), VANGUARD GROUP INC (12.62K), UBS Group AG (4.53K).
• The biggest sellers of Senti Biosciences for the quarter ending December 2025 included GEODE CAPITAL MANAGEMENT, LLC (8.04K), Bank Of America Corp /De/ (825).
• Senti Biosciences's 10 largest shareholders as of December 2025 include NEA Management Company, LLC (3.78Mn), Nantahala Capital Management, LLC (888.0K), VANGUARD GROUP INC (628.7K), GEODE CAPITAL MANAGEMENT, LLC (144.8K), Virtu Financial LLC (44.41K), JANE STREET GROUP, LLC (38.43K), MSOP GP, L.L.C. (35.74K), BlackRock, Inc. (23.38K), Northern Trust Corp (16.78K), State Street Corp (10.01K) per Business Quant data.